Aislinn Williams

List of Publications by Year
in descending order

22 papers	1,861 citations	687363 13 h-index	794594 19 g-index
23 all docs	23 docs citations	23 times ranked	2717 citing authors

#	Article	IF	Citations
1	Deletion of the voltageâ€gated calcium channel, <scp>Ca_V1</scp>.3, causes deficits in motor performance and associative learning. Genes, Brain and Behavior, 2022, 21, e12791.	2.2	5
2	SCN2A channelopathies in the autism spectrum of neuropsychiatric disorders: a role for pluripotent stem cells?. Molecular Autism, 2020, 11, 23.	4.9	16
3	Sex differences in the incidence of antidepressant-induced mania (AIM) in bipolar disorders. Neuropsychopharmacology, 2019, 44, 224-225.	5.4	5
4	Cohort Profile: The Heinz C. Prechter Longitudinal Study of Bipolar Disorder. International Journal of Epidemiology, 2018, 47, 28-28n.	1.9	58
5	T101. Accelerated Maturation Phenotypes in Patient-Derived Cell Models of Bipolar Disorder. Biological Psychiatry, 2018, 83, S167-S168.	1.3	0
6	Risk Factors Associated With Antidepressant Exposure and History of Antidepressant-Induced Mania in Bipolar Disorder. Journal of Clinical Psychiatry, 2018, 79, .	2.2	15
7	Putative biological predictors of treatment response in bipolar disorders. Personalized Medicine in Psychiatry, 2017, 1-2, 39-58.	0.1	1
8	716. Abnormal Calcium Signaling Dynamics in iPSC-Derived Bipolar Disorder Neurons. Biological Psychiatry, 2017, 81, S290.	1.3	0
9	Atypical psychotic symptoms and Dandyâ€“Walker variant. Neurocase, 2016, 22, 472-475.	0.6	7
10	Deletion of fibroblast growth factor 22 (FGF22) causes a depression-like phenotype in adult mice. Behavioural Brain Research, 2016, 307, 11-17.	2.2	23
11	The best-laid plans go oft awry: synaptogenic growth factor signaling in neuropsychiatric disease. Frontiers in Synaptic Neuroscience, 2014, 6, 4.	2.5	36
12	JosD1, a Membrane-targeted Deubiquitinating Enzyme, Is Activated by Ubiquitination and Regulates Membrane Dynamics, Cell Motility, and Endocytosis. Journal of Biological Chemistry, 2013, 288, 17145-17155.	3.4	63
13	Corrigendum to â€œIn vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesisâ€[Neurobiology of Disease 33/3 (2009) 342â€“353]. Neurobiology of Disease, 2012, 46, 503.	4.4	0
14	The Machadoâ€“Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability. Human Molecular Genetics, 2011, 20, 141-154.	2.9	129
15	In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis. Neurobiology of Disease, 2009, 33, 342-353.	4.4	97
16	Polyglutamine neurodegeneration: protein misfolding revisited. Trends in Neurosciences, 2008, 31, 521-528.	8.6	325
17	The Deubiquitinating Enzyme Ataxin-3, a Polyglutamine Disease Protein, Edits Lys63 Linkages in Mixed Linkage Ubiquitin Chains. Journal of Biological Chemistry, 2008, 283, 26436-26443.	3.4	226
18	SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model. Journal of Clinical Investigation, 2008, 118, 659-70.	8.2	282

#	Article	IF	Citations
19	Redox modifier genes in amyotrophic lateral sclerosis in mice. Journal of Clinical Investigation, 2007, 117, 2913-2919.	8.2	131
20	CHIP Suppresses Polyglutamine Aggregation and ToxicityIn VitroandIn Vivo. Journal of Neuroscience, 2005, 25, 9152-9161.	3.6	217
21	IP3Receptors and Associated Ca2+Signals Localize to Satellite Cells and to Components of the Neuromuscular Junction in Skeletal Muscle. Journal of Neuroscience, 2003, 23, 8185-8192.	3.6	40
22	Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 9310-9315.	7.1	185